Moderna's mRNA Flu Vaccine Application Rejected by FDA Amid Controversy

The FDA has denied Moderna's application to review its first mRNA seasonal flu vaccine, citing inadequate trial standards. The agency claimed the control arm of the trial did not meet the best available standard of care in the U.S. at the time. Moderna expressed frustration, stating that the FDA had previously approved their trial design and suggested they would review the application. This refusal follows a broader trend of diminished support for mRNA technology from the current administration, which has recently canceled multiple mRNA vaccine projects. The outcome affects public health efforts and vaccine development in the U.S.

Key Details: • Moderna's application was rejected due to trial design concerns. • The FDA previously approved the trial design in April 2024. • The refusal reflects a shift in support for mRNA technology by the current administration.